Transcutaneous Electrical Nerve Stimulation (TENS) is a non-invasive electrotherapy modality that delivers low-voltage electrical pulses through skin-surface electrodes to modulate peripheral nerve activity for symptomatic pain relief. In the medical device industry, a TENS device is a regulated electromedical product, typically FDA Class II under 21 CFR 882.5890 and governed by IEC 60601-2-10 particular safety requirements.
What is Transcutaneous Electrical Nerve Stimulation (TENS)?
Transcutaneous Electrical Nerve Stimulation (TENS) refers to a family of powered, battery-operated devices that generate controlled pulsed currents delivered through hydrogel or self-adhesive electrodes placed on intact skin. The pulses stimulate sensory nerve fibers to alter pain signal transmission, most commonly for symptomatic relief of chronic intractable pain, post-surgical pain, and post-traumatic pain.
In the medical device lifecycle, TENS sits within the broader electrotherapy category alongside neuromuscular electrical stimulation (NMES) and interferential current therapy. Devices range from prescription clinical units to over-the-counter (OTC) home-use products, each with distinct regulatory pathways, labeling requirements, and safety expectations.
Why Transcutaneous Electrical Nerve Stimulation (TENS) matters in medical device development
TENS devices deliver electrical energy directly to the human body, so design errors carry real patient-safety consequences: skin burns from excessive current density, electrode chemistry issues, uncontrolled output during single-fault conditions, and interference with implanted cardiac devices. Each risk maps to a specific clause in IEC 60601-1 or IEC 60601-2-10 that a manufacturer must demonstrate compliance with.
The regulatory stakes are equally material. Missing a required output-limit test can extend a 510(k) review cycle by months. Inadequate biocompatibility data on the electrode-skin interface can trigger an FDA Additional Information request. Weak post-market surveillance on an OTC TENS product raises audit exposure under FDA QMSR (21 CFR Part 820, effective February 2026) and EU MDR 2017/745. For OEMs, getting the safety architecture right early is the difference between a clean submission and a costly re-verification loop.
How Transcutaneous Electrical Nerve Stimulation (TENS) works
A TENS device is a compact pulse generator with an electrode interface, a user control layer, and a safety layer. The functional blocks typically include:
- Power source. A regulated low-voltage DC supply, usually from a rechargeable lithium cell or replaceable alkaline batteries.
- Waveform generator. A microcontroller-driven circuit that produces biphasic or monophasic pulses. Key parameters are pulse amplitude (mA), pulse width (typically 50 to 400 microseconds), and frequency (typically 2 to 150 Hz).
- Output stage. An isolation transformer or equivalent barrier that limits patient leakage current and prevents DC injection into tissue.
- Electrode interface. Hydrogel pads or reusable carbon-rubber electrodes conforming to the skin, evaluated per the ISO 10993 series for biocompatibility.
- User controls and display. Intensity, mode, and timer controls are designed under IEC 62366-1 usability engineering principles.
- Software and firmware. Where applicable, the embedded system is classified and developed under IEC 62304.
Safety-critical behavior includes automatic shutoff on open electrode conditions, output limits under fault, and clear on-device markings. IEC 60601-2-10 specifies the output waveform verification, maximum output values, and patient leakage current tests. Risk management follows ISO 14971, with hazards traced from analysis through verification evidence and residual risk acceptance.
Common challenges and best practices
Teams building a TENS device tend to run into a few recurring issues.
Electrode-skin interface control. The current density at the electrode edge is often higher than designers assume. Best practice is to specify electrode geometry, gel formulation, and adhesion characteristics as controlled design outputs, then verify with worst-case skin impedance simulations.
Output limits under single-fault. Reviewers focus closely on what happens if a component shorts or the microcontroller hangs. Independent hardware limiters, not firmware-only limits, are the accepted approach.
Contraindication labeling. Every TENS device must carry clear warnings against use over the carotid sinuses, on patients with implanted pacemakers or defibrillators, during pregnancy near the abdomen, and on damaged skin. Labeling gaps are a common Form 483 finding.
OTC versus prescription framing. The two pathways have different indications for use, different human factors expectations, and different post-market surveillance obligations. Choose the pathway before design freeze, not after.
Home-use environment. IEC 60601-1-11 applies to home healthcare use. EMC per IEC 60601-1-2 gets tighter, and instructions for use must be written for lay users.
How SJML helps with Transcutaneous Electrical Nerve Stimulation (TENS)
Electrotherapy is a served segment for Syrma Johari MedTech (SJML), and TENS platforms sit within the company’s established rehabilitation and physical therapy portfolio. SJML supports OEMs across the full path: electromechanical design, embedded firmware and user interface, waveform engineering, and usability work under IEC 62366-1. In-house labs cover electrical safety to IEC 60601-1 and IEC 60601-2-10, EMC testing, and reliability and environmental testing. Manufacturing includes medical PCBA, cable harnesses, and cleanroom assembly, backed by process validation and traceability. QARA teams handle 510(k) submissions, CE marking under EU MDR, and post-market surveillance.
Talk to SJML’s engineering team →
Frequently asked questions
Most Transcutaneous Electrical Nerve Stimulation (TENS) devices are classified as FDA Class II under 21 CFR 882.5890, with product code GZJ for prescription pain relief and NUH for OTC pain relief. Powered muscle stimulation functions fall under 21 CFR 890.5850, product code IPF. A 510(k) submission is the standard premarket pathway for both prescription and OTC variants.
IEC 60601-2-10 is the particular standard for the basic safety and essential performance of nerve and muscle stimulators, applied together with the IEC 60601-1 general standard. IEC 60601-1-2 covers electromagnetic compatibility. For home-use devices, IEC 60601-1-11 adds requirements for the home healthcare environment, including tighter EMC and lay-user labeling.
TENS targets sensory nerve fibers to modulate pain perception at relatively low amplitudes and short pulse widths. NMES (neuromuscular electrical stimulation) uses higher amplitudes and wider pulse widths to produce muscle contraction for muscle re-education. Many combination devices offer both modes and must satisfy both 21 CFR 882.5890 and 21 CFR 890.5850, along with all applicable IEC 60601-2-10 tests.
TENS electrodes are surface-contacting devices with prolonged skin contact, so ISO 10993-1 categorization typically calls for cytotoxicity (ISO 10993-5), sensitization and irritation (ISO 10993-10 and 10993-23), and material characterization (ISO 10993-18). Adhesive hydrogels also require stability data across the labeled shelf life. Reviewers expect a documented biological evaluation plan and report tied to the finished device configuration.
Yes. FDA cleared OTC TENS devices under 21 CFR 882.5890 for temporary relief of pain associated with sore and aching muscles. OTC clearance requires stricter output limits, robust human factors validation under IEC 62366-1 for lay users, and labeling that a non-clinician can safely follow. Prescription indications, including chronic intractable pain, remain restricted to prescription products.
Related terms
- IEC 60601-1
- IEC 60601-2-10
- ISO 14971 Risk Management
- 510(k) Premarket Notification
- Neuromuscular Electrical Stimulation (NMES)
